Choosing the Right Insulin for Canine Diabetes Mellitus

Long-term management of canine diabetes mellitus extends beyond initiating insulin therapy; it requires selecting an insulin formulation that complements the patient's clinical needs and supports sustained glycaemic control. While several insulin preparations are available for use in dogs, they differ in formulation, duration of action and clinical performance. As a result, selecting the most appropriate insulin is an important part of treatment planning and may influence both the quality of glycaemic control and the ease of long-term disease management¹. 

Most dogs can be successfully managed using licensed veterinary insulin formulations. However, some patients remain difficult to regulate despite appropriate dosing, making familiarity with alternative insulin options valuable in clinical practice. 

Understanding the Available Insulin Options 

Insulins used for chronic management are intended to provide a continuous background, or basal, insulin effect that helps minimise prolonged hyperglycaemia while reducing the likelihood of excessive hypoglycaemia. These preparations are generally classified as intermediate-acting or long-acting, although their duration of action may overlap in individual dogs¹. 

Rapid-acting preparations, including regular insulin and rapid-acting analogue insulins, have a different clinical role. Rather than serving as maintenance therapy, they are primarily reserved for emergency situations such as diabetic ketoacidosis or hyperosmolar hyperglycaemic states, where rapid correction of hyperglycaemia is required. 

Licensed Veterinary Insulins: The Foundation of Long-Term Therapy 

Porcine lente insulin remains one of the most widely used insulin preparations for managing canine diabetes mellitus. Licensed veterinary formulations contain porcine insulin at a concentration of 40 U/mL and combine semilente and ultralente insulin to provide an intermediate duration of activity. 

Following subcutaneous administration, blood glucose concentrations typically reach their nadir approximately 4–8 hours after injection, while glucose-lowering effects may persist between 8 and 24 hours¹. Clinical response, however, varies between individual dogs. 

Although initial once-daily administration is recommended by the manufacturer, clinical experience has shown that many dogs require twice-daily administration to achieve satisfactory control. Approximately two-thirds of dogs required conversion to twice-daily therapy when clinical signs persisted or blood glucose concentrations remained above the desired range for prolonged periods^1,2. Conversely, some dogs demonstrate insulin activity exceeding 12 hours, emphasising the importance of individual assessment before increasing dosing frequency because of the potential risk of hypoglycaemia¹. 

Protamine zinc insulin (PZI) provides another licensed veterinary option. Its prolonged duration of action may be advantageous in dogs where shorter-acting preparations fail to provide adequate glycaemic coverage throughout the dosing interval. However, considerable variation in onset, nadir, and duration has also been reported, highlighting the need for ongoing monitoring during treatment^1,3. 

When Alternative Insulin Preparations May Be Considered 

While licensed veterinary products remain appropriate for most patients, some dogs continue to exhibit inconsistent glycaemic control despite appropriate management. In these situations, long-acting analogue insulins such as glargine, detemir and degludec may be considered. 

These preparations differ from traditional formulations in the way they prolong insulin activity, resulting in distinct clinical profiles. Rather than assuming one analogue is universally preferable, selection should be guided by the individual dog's response, treatment goals and overall glycaemic pattern. 

One practical consideration involves insulin detemir, which achieves glycaemic control at lower doses than many other insulin preparations. Careful dose selection is therefore essential, particularly in smaller dogs where precise dose administration may be more challenging^1,2. 

Practical Clinical Insights 

Selecting an insulin formulation should involve more than simply choosing a licensed product. Useful considerations include: 

• Assess whether the insulin provides adequate coverage throughout the intended dosing interval. 

• Base treatment adjustments on both clinical signs and objective monitoring. 

• Recognise that individual dogs may require different dosing frequencies despite receiving the same insulin formulation. 

• Consider an alternative insulin when persistent instability appears related to inadequate or excessive duration of action. 

• Introduce changes cautiously, recognising that insulin response varies between patients. 

Conclusion 

Choosing an insulin for canine diabetes mellitus is an ongoing clinical decision rather than a one-time therapeutic choice. Licensed veterinary formulations remain suitable for most diabetic dogs, but treatment should always be individualised according to clinical response and glycaemic control. Understanding the strengths and limitations of available insulin preparations enables veterinarians to make informed adjustments when regulation proves challenging, supporting safer and more effective long-term diabetes management. 

Reference 

1. Shiel RE, Mooney CT. Insulins for the long term management of diabetes mellitus in dogs: a review. Canine medicine and genetics. 2022 Feb 14;9(1):1. https://link.springer.com/content/pdf/10.1186/s40575-022-00114-9.pdf 

2. Behrend E, Holford A, Lathan P, Rucinsky R, Schulman R. 2018 AAHA diabetes management guidelines for dogs and cats. Journal of the American Animal Hospital Association. 2018 Jan 1;54(1):1-21. https://www.drlawrenvet.com/s/diabetes-guidelines_final.pdf 

3. Ward CR, Christiansen K, Li J, Bryson WL, Jerrentrup KA, Kroh C. Field efficacy and safety of protamine zinc recombinant human insulin in 276 dogs with diabetes mellitus. Domestic animal endocrinology. 2021 Apr 1;75:106575. https://www.sciencedirect.com/science/article/pii/S0739724020301429